Special Issue

Current Advances and Perspectives in Intrahepatic Cholangiocarcinoma

Message from the Guest Editors

We are pleased to invite you to contribute to the upcoming Special Issue on "current advances and perspectives in intrahepatic cholangiocarcinoma".

Cholangiocarcinoma (CCA) is the second most common primitive liver cancer. Despite recent advances in its surgical management, the prognosis remains poor, with a 5-year survival rate of less than 5%. Intrahepatic CCA (iCCA) has a median survival of between 18 and 30 months, but if deemed unresectable this decreases to 6 months. Most patients experience a liver-confined disease that is considered unresectable because of its localization, the infiltration of vascular structures, or its multifocality.

In this Special Issue, original research articles and reviews are welcome. Research areas of interest include the following: the tumour microenvironment, diagnostic and prognostic biomarkers, surgery, resectable disease, the role of adjuvant therapy, liver-directed therapies, the management of oligometastatic disease, targeted therapies, and future directions

We look forward to receiving your contributions.

Guest Editors

Dr. Marco Massani

HPB Hub Reference Center, First General Surgery Unit, Department of Surgery, Azienda ULSS2 Marca Trevigiana, 31100 Treviso, Italy

Dr. Tommaso Stecca

HPB Hub Reference Center, First General Surgery Unit, Department of Surgery, Azienda ULSS2 Marca Trevigiana, 31100 Treviso, Italy

Deadline for manuscript submissions

closed (30 June 2022)



Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed



mdpi.com/si/100563

Journal of Clinical Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcm@mdpi.com

mdpi.com/journal/ jcm





Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).